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Background: This systematic review was requested by
the Task Force of the American Academy of Periodontology
as a follow-up study of the 2013 report, with an aim to inves-
tigate the efficacy of different surgical approaches to treat
peri-implantitis.
Methods: A search of four electronic databases from
January 1990 to May 2013 was performed. Studies included
were human clinical trials published in English that applied
surgeries for treating peri-implantitis. Parameters evaluated
included probing depth (PD) reduction, clinical attachment
level gain, bleeding on probing (BOP) reduction, radio-
graphic bone fill (RBF), and mucosal recession. The
weighted mean (WM) and the 95% confidence interval of
the studied parameters were estimated with the random-
effect model.
Results: A total of 1,306 studies were initially identified,
after reviewing titles, abstracts, and full texts, and 21 arti-
cles, 12 of which were case series, were finally included.
Four treatment groups were identified: 1) access flap and
debridement; 2) surgical resection; 3) application of bone
grafting materials; and 4) guided bone regeneration. The
mean initial PD ranged from 4.8 to 8.8 mm, with initial
BOP ranging from 19.7% to 100%. Short-term follow-ups
(3 to 63 months) revealed that the available surgical pro-
cedures yielded a WM PD reduction of 2.04 (group 2) to
3.16 mm (group 4), or 33.4% to 48.2% of the initial PD.
The WM RBF was 2.1 mm for groups 3 and 4.
Conclusions: Within the limitation of this systematic re-
view, the application of grafting materials and barrier mem-
branes resulted in greater PD reduction and RBF, but there
is a lack of high-quality comparative studies to support this
statement. The results might be used to project treatment
outcomes after surgical management of peri-implantitis.
J Periodontol 2014;85:1027-1041.
KEY WORDS
Anti-infective agents; debridement; guided tissue
regeneration; osseointegration; peri-implantitis; treatment
outcome.
W
ith an increasing number of
implants being placed, peri-
implantitis is becoming a prev-
alent and notable disease, affecting
2.7% to 47.1% of implants.1-5 Identical
to periodontitis, microbial plaque is the
main etiologic factor of peri-implantitis.6
It has been shown that the infected sites
harbor a higher proportion of periodontal
pathogens.7,8 Because peri-implantitis
shares many features of periodontitis,9
such as clinical presentations, etiology,
and pathogenesis, strategies used to treat
periodontitis were adopted for managing
peri-implantitis.10,11 These non-surgical
or surgical approaches share common
goals of eliminating infection and re-
storing lost structures and function. Al-
though effective in treating peri-implant
mucositis, non-surgical therapy is unable
to eradicate peri-implantitis.12 The surgi-
cal therapy is currently the mainstream
approach for treating peri-implantitis.13 A
contained, deep defect may be amenable
for regeneration, whereas a shallow de-
fect may respond more favorably with
resective surgery. With the rising preva-
lence of peri-implantitis, there is an urgent
need to identify an effective treatment
procedure.
One of the goals of surgical therapy
is to gain access for effective surface
decontamination. Surfaces contaminated
by microbes are not conducive to
bone-forming cells; therefore, surface
decontamination is critical for reos-
seointegration. Mechanical means of
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surface detoxification
have been used exten-
sively.14,15 Implanto-
plasty is a more radical
way of mechanical sur-
face treatment, and it
has been shown to halt
marginal bone loss ef-
fectively.16,17 Chemo-
therapy, which includes
applications of root con-
ditioners, disinfectants,
and antibiotics on the




dioxide (CO2) and er-
bium:yttrium–aluminum–
garnet (Er:YAG) lasers
have shown some prom-
ising results,20-23 yet the
most effective protocol
for implant surface de-




the degree of inflam-
mation resolution, probing
depth (PD) reduction,
and bone fill, are in-
dicators for evaluat-
ing the effectiveness




enable a systematic in-
vestigation of the over-
all performance of each
surgical procedure. As
a continuous effort of
the 2013 report27 di-
rected by the Task




with a focused ques-
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MATERIALS AND METHODS
Inclusion and Exclusion Criteria
Included studies were human clinical trials comprising
case series (CS), cohort studies, quasi-experiments
(QEs), and randomized controlled trials (RCTs) that
1) were published in the English language; 2) ap-
plied surgeries for treating peri-implantitis; 3) re-
ported on at least one clinical or radiographic
parameter; 4) had a minimum sample size of eight
implants; and 5) followed the treated implants for at
least 3 months for surgical interventions other than
regenerative procedures, which had a follow-up
period of 6 months or more.
Screw-shaped implants with either smooth or
rough surfaces were included. There was no re-
striction on the methods for surface detoxification
used. Animal studies, reviews, and case reports were
excluded, but the bibliographies of these studies
were screened for potential articles to be included.
The parameters included the following: 1) PD re-
duction (in millimeters); 2) clinical attachment level
(CAL) gain (in millimeters); 3) bleeding on probing
(BOP) reduction (percentage); 4) radiographic bone
fill (RBF) (in millimeters); and 5) mucosal recession
(MR) (in millimeters).
Search Strategy
A search of four electronic databases, including
Ovid MEDLINE, PubMed, EMBASE, and Dentistry
and Oral Sciences Source, for relevant studies pub-
lished in the English language from January 1990 to
May 2013 was performed. The search terms used, in
which mh represented the MeSH terms and tiab rep-
resented title and/or abstract, included the following:
(‘‘peri-implantitis’’[mh] OR ‘‘peri-implantitis’’[ti] OR
((‘‘dental implantation, endosseous’’[mh] OR ‘‘dental
implants’’[mh]) AND (‘‘peri implant’’[tiab] OR ‘‘peri-
implantitis’’[tiab]))) AND (‘‘treatment’’[tiab] OR ‘‘ther-
apy’’[tiab] OR ‘‘therapeutics’’[tiab] OR ‘‘surgery’’[tiab]
OR ‘‘surgical’’[tiab] OR ‘‘regeneration’’[tiab] OR
‘‘regenerative’’[tiab] OR ‘‘guided tissue regenera-
tion’’[mh] OR ‘‘bone graft’’[tiab] OR ‘‘bone graft-
s’’[tiab] OR ‘‘bone substitute’’[tiab] OR ‘‘bone
substitutes’’[tiab] OR ‘‘access flap’’[tiab] OR ‘‘open
flap’’[tiab] OR ‘‘debridement’’[tiab] OR ‘‘resective’’[tiab]
OR ‘‘implantoplasty’’[tiab] OR ‘‘laser’’[tiab] OR ‘‘la-
sers’’[tiab]).
A hand search was also performed in dental and
implant-related journals from January 2000 to April
2013, including the following: 1) Journal of Peri-
odontology; 2) Clinical Implant Dentistry and Re-
lated Research; 3) International Journal of Oral and
Maxillofacial Implants; 4) Clinical Oral Implants
Research; 5) Implant Dentistry; 6) International
Journal of Oral and Maxillofacial Surgery; 7) Jour-
nal of Oral and Maxillofacial Surgery; 8) Journal of
Dental Research; 9) Journal of Prosthetic Dentistry;
10) International Journal of Prosthodontics; 11)
Journal of Oral Implantology; 12) Journal of Clinical
Periodontology; and 13) International Journal of
Periodontics & Restorative Dentistry. European
Journal of Oral Implantology was searched from
January 2008 to April 2013. Furthermore, a search
in the references of included papers was conducted
for publications that were not electronically identi-
fied. One examiner (G-HL) performed all the
searches. Potential articles were examined in full text
by two reviewers (G-HL and H-LC), and their eligi-
bility for this review was confirmed after discussion.
The level of agreement between the reviewers re-
garding study inclusion was calculated using k
statistics. The screening process was shown in
supplementary Figure 1 in online Journal of Peri-
odontology.
Risk of Bias Assessment
The criteria used to assess the quality of the selected
RCTs were modified from the RCT checklist of the
Cochrane Center28 and the CONSORT (Consoli-
dated Standards of Reporting Trials) statement.29
The degree of bias was categorized as follows: 1) low
risk if all the criteria were met; 2) moderate risk
when only one criterion was missing; and 3) high
risk if two or more criteria were missing. Two re-
viewers (G-HL and H-LC) assessed all the included
articles independently, and final assessment was
achieved with discussion.
Data Extraction
Data were extracted by two observers (G-HL and
H-LC) independently. Disagreements were resolved
with discussion after carefully reviewing the studies in
question. Demographic information was recorded for
each study, including the following: 1) study design;
2) sample size; 3) number of fixtures placed; 4) lo-
cation of the implants; 5) surgical technique used; 6)
loading protocols; and 7) follow-up period.
Data Analyses
The primary outcome was the amount of PD re-
duction. The percentage of PD reduction was cal-
culated as the amount of PD reduction divided by the
amount of initial PD. The same calculation was
performed for the percentage of CAL gain. The
weighted mean (WM) and the 95% confidence in-
terval (CI) of the variables were estimated using
a computer program.‡ The random-effect model was
applied when performing meta-analyses to account
for methodologic differences among studies. Forest
plots were produced to graphically represent WM and
‡ Comprehensive Meta-Analysis v.2, Biostat, Englewood, NJ.
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95% CI of the outcomes using
‘‘implant’’ as the analysis unit.
For studies with multiple treat-
ment groups, the results from
groups of the same category
were combined together. Het-
erogeneity was assessed with
the I2 test, which ranges from
0% to 100%, with a lower value
representing less heterogene-
ity. The reporting of these
meta-analyses adhered to the
PRISMA (Preferred Reporting




The screening process was
shown in supplementary Figure
1 in the online Journal of Peri-
odontology. Electronic and
hand searches yielded 1,306
articles, of which 34 articles
were selected for full-text eval-
uation after screening their ti-
tles and abstracts. Thirteen
articles15,31-42 were further
excluded; the reasons for exclu-
sion are listed in supplemen-
tary Table 1 in online Journal
of Periodontology. Twenty-
one16,18-23,43-56 articles were
finally included. The main fea-
tures and conclusions of the
included studies are summa-
rized in Table 1. The outcomes
of various parameters for each
included study are presented in
Table 2.
The k value for inter-reviewer
agreement for potentially rele-
vant articles was 1 (titles and
abstracts) and 0.85 (full-text
articles), indicating an ‘‘almost
perfect’’ agreement between
the two reviewers according






and five RCTs16,19,21,43,44 were
Figure 1.
A)Meta-analysis for the amount of PD reduction among selected studies using intervention of access
flap and debridement. The WM was 2.38 mm, with a 95% CI of 1.86 to 2.91 mm. B)Meta-analysis for
the amount of PD reduction among selected studies using intervention of resective approach. The WM
was2.04mm, with a 95%CI of 1.87 to 2.19mm.C)Meta-analysis for the amount of PD reduction among
selected studies using intervention of regenerative treatment with grafting materials. The WM was
2.32 mm, with a 95% CI of 1.04 to 3.61 mm. D)Meta-analysis for the amount of PD reduction among
selected studies using intervention of regenerative treatment with both grafting materials and barrier
membranes. The WM was 3.16 mm, with a 95% CI of 2.54 to 3.78 mm. red = reduction.
Surgical Treatment of Peri-Implantitis Volume 85 • Number 8
1034
included. Patient age ranged from 24 to 83 years.56
Fourteen studies16,18,19,21-23,43,44,49,51-55 included
smokers, one study included non-smokers50 exclu-
sively, and six studies20,45-48,56 did not report
the smoking status of the participants. Informa-
tion about the location of the treated implants is
listed in Table 1. Four stud-
ies20,49,51,56 did not report in-
formation about the features
of the treated implants; some
implants were reported as hav-
ing non-identifiable features in
two studies.21,22 Three stud-
ies18,50,54 included smooth and
rough surface implants, whereas
in seven studies,16,19,43,46-48,52
only rough-surface implants
were included. In two stud-
ies,45,55 the information about
the implant features was not
available because the features
of the failed implants excluded
at the final examination were
not released.
Defect Features
The mean initial defect depth
was measured radiographi-
cally or clinically in most
studies; four studies16,45,51,52
did not report it. The mean
initial PD was also reported
in most studies, except for
four studies.47,51,53,56 It ranged
from 4.845 to 8.846 mm. Nine
articles16,20-22,45,49,50,54,55
measured the mean initial
CAL, with a range of 5.516
to 9.149 mm. Eleven stud-
ies18,21-23,43,44,49,50,52,55,56
reported the mean initial BOP
in percentage, with a range of
19.7%49 to 100%.50
Surgical Features
Four treatment groups were
identified: 1) access flap and
debridement only;18,19,45,50 2)
resective approach;16,44 3) ap-




grafting materials used in-
cluded autografts,20,43,45,47,48
a combination of autografts
and xenografts,56 allografts,46 alloplastic mate-
rials,55 xenografts,20-23,43,46,49,52,55 and others.19,51,53,54
Non-resorbable20-23,43,46,48,49,53-55 and resorb-
able45,47,48 membranes were used. Five stud-
ies19,45,47,48,54 submerged the implants. In one
study,20 four implants were submerged, whereas
Figure 2.
A)Meta-analysis for the percentage of PD reduction among selected studies using intervention of
access flapand debridement. TheWMwas37.9%,with a 95%CI of 29.1% to47.6%.B)Meta-analysis for
the percentage of PD reduction among selected studies using intervention of resective approach. The
WMwas 33.4%, with a 95% CI of 21.5% to 47.9%.C)Meta-analysis for the percentage of PD reduction
among selected studies using intervention of regenerative treatment with grafting materials. The WM
was37.1%,with a 95%CI of 21.1% to56.5%.D)Meta-analysis for the percentage of PD reduction among
selected studies using intervention of regenerative treatment with both grafting materials and barrier
membranes. The WM was 48.2%, with a 95% CI of 38.6% to 57.9%. red = reduction.
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12 implants were not. Implants were not submerged
in the remaining studies.
Surface Treatment
The contaminated implant surfaces were primar-
ily treated with mechanical means, including air
abrasives,45,46,49,50 curets made of different ma-
terials (plastics,18,21,22,50,52,55 carbon,23 stainless
steel,49 graphite,46 and titanium19,20,51), and im-
plantoplasty.16,21-23,44,56 Chemotherapy was com-
monly accompanied with mechanical debridement.
The agents used were chlorhexidine,18,44,48,52 ce-
tylpyridinium chloride (CPC),44 citric acid,48 tetra-
cycline,46,51 hydrogen peroxide,43,48,53-55 and
EDTA.19,52 Compared with the placebos, chlo-
rhexidine and CPC did not result in significantly
better clinical outcomes,44 although they had the
ability to suppress growth of anaerobic bacteria.
Implantoplasty with resective surgery was associ-
ated with a higher implant survival rate, more PD
reduction, and reduced bone loss compared with
resective surgery alone.16,17 Precaution should be
exercised when performing implantoplasty on
narrower implants because of weakening the im-
plant structure, which could potentially lead to
fracture of the fixture.58 The CO2, diode, and Er:
YAG lasers were applied in
some studies.20-23,45,47 Com-
parative studies were con-
ducted by Deppe et al.45 and
Schwarz et al.21 to evaluate
the effects of using CO2 and
Er:YAG lasers, respectively.
No statistically significant dif-
ferences in all assessed pa-
rameters could be found.
Therefore, the limited evidence
suggested that these lasers
generated similar treatment
outcomes as hand curets.
Results of the Meta-Analyses
The results and forest plots of
the meta-analyses for PD re-
duction and RBF are demon-
strated in Figures 1 through 3;
the outcomes of various pa-
rameters for each surgical in-
tervention are presented in
Table 3.
Implants treated with access
flap and debridement had aWM
PD reduction of 2.38 mm (95%
CI: 1.86 to 2.91 mm; Fig. 1A)
or 37.9% (95% CI: 29.1% to
47.6%; Fig 2A). Only one arti-
cle19 reported RBF (0.1 – 1.9mm). TheWMCAL gain
was 1.20 mm (95% CI: -0.91 to 3.31 mm)45,50 or
2.22%.45 Two articles18,50 reported the percentages
of BOP at baseline and the last follow-up, which
yielded 41.1% BOP reduction. TheWMMRwas 1.31 –
0.61 mm.18,45
Implants treated with the resective surgery had
a WM PD reduction of 2.04 mm (95% CI: 1.87 to 2.91
mm; Fig. 1B) or 33.4% (95% CI: 21.5% to 47.9%; Fig.
2B).16,44 Only one article16 reported CAL gain (-0.28
– 0.88 mm, equivalent to -4.3%). The BOP reduction
was 21.2%, reported in one article.44 TheWMMR was
1.44 – 0.39 mm.16 The amount of RBF was not re-
ported.
Five articles19,48,52,55,56 evaluated the effect of
bone grafting on treating peri-implantitis. TheWM PD
was 2.32 mm (95% CI: 1.04 to 3.61 mm; Fig. 1C) or
37.1% (95% CI: 21.1% to 56.5%; Fig. 2C). The WM
RBF was 2.10 mm (95% CI: 1.47 to 2.72 mm; Fig.
3A).19,48,51-53,56 Only one article55 reported the
amount of CAL gain (0.6 – 0.5 mm, equivalent to
8.2%). The percentage of BOP reduction was
39.6%.52,55,56 The WM MR was 0.87 – 0.88 mm.55,56
Implants treated with GBR had WM PD re-
duction of 3.16 mm (95% CI: 2.54 to 3.78 mm;
Fig. 1D) or 48.2% (95% CI: 38.6% to 57.9%;
Figure 3.
A)Meta-analysis for the amount of defect fill among selected studies using intervention of
regenerative treatment with grafting materials. TheWMwas 2.10 mm, with a 95% CI of 1.47 to 2.72
mm. B) Meta-analysis for the amount of defect fill among selected studies using intervention of
regenerative treatment with both grafting materials and barrier membranes. The WM was 2.16 mm,
with a 95% CI of 1.36 to 2.96 mm.
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Fig. 2D).20-23,43,45,46,48,49,54,55 Seven arti-
cles43,46-49,53,54 reported a WM RBF of 2.16 mm
(95% CI: 1.36 to 2.96 mm; Fig. 3B). The WM CAL
was 1.99 – 0.46 mm21-23,45,49,54,55 or 28.1%.
The WM BOP reduction was 50.2%.21-23,43,49,55
The WM MR was 0.39 – 0.28 mm.21-23,45,49,55
The results of the heterogeneity test are shown in
Table 3. All P values for the x2 test were >0.1, and I2
test values were <50%, representing a low to mod-
erate heterogeneity among included studies. Be-
cause of the small number of selected studies,
comparisons among different bone grafting mate-
rials, membrane types, and healing protocols were
not performed.
Risk of Bias Assessment
The risk of bias assessment for the included RCTs is
summarized in supplementary Table 2 in online
Journal of Periodontology. One study19 was con-
sidered to have a low risk of bias, and another three
studies21,43,44 were considered to have a moderate
risk of bias; however, the one other study16 was
considered to have a high risk of bias.
DISCUSSION
Summary of Main Findings
PD reduction after surgical procedures comprised
MR, resolution of inflammation, and formation of
new attachment. This study showed that the amount
and percentage of PD reduction for each surgical
intervention was 2.38 – 0.53 mm and 37.9% for the
access flap and debridement (mean follow-up time
of 22.5 months), 2.04 – 0.15 mm and 33.4% for
resective approach (mean follow-up time of 21
months), 2.32 – 1.29 mm and 37.1% for using bone
grafting materials (mean follow-up time of 14
months), and 3.16 – 0.62 mm and 48.2% for GBR
(mean follow-up time of 14.1 months). A 2 to 3 mm
PD decrease could be expected as a result of
a surgical procedure. The highest reported PD re-
duction was 5.4 mm, achieved by regenerative
procedures.46,48 The meticulous surface de-
contamination methods as well as the use of biologic
agents might have accounted for the favorable
outcome. Nevertheless, the outcomes of the re-
generative approach are less predictable. Systemic
conditions of the patients, defect features,23 implant
surfaces,52 and materials used43 were confounding
factors that should be considered.
The results showed 2 mm RBF for surgical
procedures using bone substitutes without and with
barrier materials. The highest amount of bone fill
was reported by Wiltfang et al.56 (3.5 – 2.4 mm) and
Froum et al.46 (3.8 – 1.5 mm). The former study,
with a follow-up period of 1 year, used autolo-
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xenogenic bone grafts and bone morphogenetic
proteins. The satisfactory outcomes might be at-
tributable to the bone-forming and reosseointegra-
tion potential of the growth factors.59 The latter
study, with a follow-up period of 3 to 7.5 years,
introduced a series of sophisticated protocols for
implant surface decontamination, including use of
air-abrasive devices, tetracycline and chlorhexidine
gluconate applications, and enamel matrix de-
rivatives in combination with xenografts or allo-
grafts. These surgical protocols were based on the
authors’ clinical experiences; more controlled clini-
cal trials are thus needed to validate the proposed
treatment approach.
Barrier membranes were designed to exclude
epithelial cells and fibroblasts, thus favoring the
population of bone cells in a bony defect. Benefits of
using barrier membranes are not clear. In one
study,55 the combination of grafting materials and
a membrane appeared to yield a better clinical out-
come compared with the use of grafting material
alone. However, in another 3-year follow-up study,48
it was concluded that the additional application of
barrier membranes had no significant influence on
bone level changes. Roos-Jansåker et al.53 con-
curred that the use of barrier membranes did not
significantly improved RBF. When a membrane is
exposed, the regeneration potential of the site is di-
minished. This is especially true in the early stages of
healing.60 Evidence showed that membrane expo-
sure rates were high: 13% to 38% in animal stud-
ies14,61,62 and 18%49 to 87.6%53 in human clinical
trials. Additionally, a well-contained defect might
not require a membrane. Because application of
a membrane is costly, time consuming, and tech-
nique sensitive, its potential benefits and costs should
be carefully weighed before its use.
Four studies20,21,45,47 applied lasers during the
surgery. In a CS study,20 CO2 laser was used in
combination with either autografts or xenografts and
absorbable membranes with favorable outcomes. In
contrast, Deppe et al.45 concluded that no difference
could be detected for regenerative procedures with
or without CO2 laser treatment on a long-term basis.
More information is required to assess the benefit of
using lasers for treating peri-implantitis.
Comparison With Other Relevant Systematic
Reviews
Other systematic reviews25,26,63 that investigated the
clinical outcomes of treating peri-implantitis were
available in the literature. A direct comparison of their
results to this current analysis is not possible because
of different selection criteria for the articles, surgical
approaches, and methods of computing data. Nev-
ertheless, the reported mean amount of PD reduction
was generally compatible among the reviews. One
study26 concluded that the estimated PD reduction
was 1.53 mm at 6 months with both non-surgical and
surgical treatments. Another study25 comparing PD
reduction and CAL gain between non-surgical and
various surgical procedures showed that using bone
grafts and non-resorbable membranes resulted in the
greatest PD reduction, with 3.52-mm greater re-
duction than non-surgical therapy.
Potential Biases Related to the Review Process
Several limitations were present in the current meta-
analysis. First, the number of included papers for
each surgical procedure is low, and only some
studies compared treatment effects of different sur-
gical approaches. Second, there are various degrees
of heterogeneity in the study design, case selection,
and treatment provided among studies. Third, the
current review only includes studies written in En-
glish, which could introduce a publication bias. Last,
the patient-centered outcomemeasurements,26 such
as changes of quality of life or esthetic improve-
ments, are not analyzed in the current review.
CONCLUSIONS
Four main surgical procedures were identified for
treating peri-implantitis: 1) access flap and de-
bridement; 2) surgical resection; 3) regeneration
with bone grafts; and 4) GBR. In short-term follow-
ups, these procedures yielded an estimated 2- to 3-
mm PD reduction, equivalent to 30% to 50% of the
initial PD. A mean 2-mm RBF was achieved with
regenerative procedures. The regenerative pro-
cedures using bone graft materials in combination
with barrier membranes might be more effective;
however, the outcomes of the regenerative pro-
cedures were also the most varied. Limited evidence
suggested that implantoplasty could improve clini-
cal outcomes, and lasers might provide equivalent
effects to other commonly used methods for surface
decontamination.
Implications for Practice
Currently available surgical approaches execute
some clinical benefits, measured with surrogate
endpoints in a short term. The treatment effects on
implant survival and patient-centered outcomes are
not known. The results provided an estimated PD
reduction, among other parameters, that might be
used to project treatment outcomes. Regenerative
procedures using bone grafts and membranes
seemed to generate greater PD reduction; however,
comparative studies with low risk of bias that can
substantiate this statement were lacking. The sys-
temic condition of the patients, defect features, and
types of materials could influence outcomes and
should be assessed prudently.
Surgical Treatment of Peri-Implantitis Volume 85 • Number 8
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Implications for Research
There is an urgent need for well-designed, studies
with larger sample sizes, e.g., multicenter studies.
The potential sources of bias should be reported for
the purpose of quality assessment. Treatment out-
comes should be evaluated at a multivariable level to
identify the sources of heterogeneity. Studies on
patient-centered outcomes and implant survival rate
should be pursued. The clinical efficacy of biologic
agents and lasers deserves additional investigation.
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